Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922777 · ClinicalTrials.gov registry record · Phase 1
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02922777 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT02922777, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.
Interventions
- DRUG Docetaxel
- DRUG BGB324
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-11 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922777
The ClinicalTrials.gov registry entry for NCT02922777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT02922777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922777 about?
NCT02922777 is a clinical study titled "Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.". This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.
What is the current status of trial NCT02922777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-11. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT02922777?
The interventions under investigation include: Docetaxel (DRUG), BGB324 (DRUG).
Who is sponsoring clinical trial NCT02922777?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.